Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of risvutatug rezetecan in previously treated unresectable advanced or metastatic sarcomas
MOH_2026-07-28_016958Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of risvutatug rezetecan in osteosarcoma (OS) and soft tissue sarcoma (STS) (3 cohorts), sponsored by GSK. Started Jul 2026; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on MOH_2026-07-28_016958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-28_016958.